Pinned Tweet
A 🧵on STRONG-HF 💪🏾🫀
⭐️The first randomized trial to show the immense benefits of a comprehensive high-intensity med-titration program with #HF GDMT
❓How did the investigators achieve an 8.1% ARR in HFH/mortality at 6 months❓
Let’s see what we can learn 👇🏾🧵
Very excited to be here!
Welcoming Neal Dixit, MD (@NealDixit) to the Advanced Heart Failure and Transplant Cardiology faculty!
@UCSDCardFellows @UCSDHealthSci @ucsdim
Neal Dixit, MD retweeted
Won’t 💊 cost too much?
With generic pricing: $3.5 billion a year
Optimal implementation in eligible patients with HF, CKD & T2DM is projected to:
🏥 Reduce billions in CV/HF 🏨s
🫘 Avoid dialysis costs in CKD
Not prescribing SGLT2i way more costly
#SGLT2i #ValueBasedCare
Excited to share our review on predicting sudden cardiac death in HFrEF led by outstanding med student Norayr Mkrtchyan!
It's a comprehensive look at the risk factors associated with sudden death in this population
@AntoinetteBirs @AHajduczok
link.springer.com/article/10…
Neal Dixit, MD retweeted
Is finerenone ready for primetime in heart failure? We argue that the data suggest not yet. @NealDixit @cardiologyUc #AHAJournals ahajrnls.org/3Gn7QkZ
Is it primetime for finerenone in HF?
Would love to hear why or why not?
Here is our perspective 👇🏾
ahajournals.org/doi/10.1161/…
Neal Dixit, MD retweeted
Congrats @NealDixit !!! Can’t wait for you to join the awesome team at @UCSDCardiology ❤️
Ecstatic to share that I will be joining @HowieTranMD and the team at @UCSDCardFellows for Advanced Heart Failure and Transplant Cardiology Fellowship!
Ecstatic to share that I will be joining @HowieTranMD and the team at @UCSDCardFellows for Advanced Heart Failure and Transplant Cardiology Fellowship!
Neal Dixit, MD retweeted
Is Finerenone just an expensive spironolactone?
"A RCT of nonsteroidal versus steroidal MRAs is desperately needed in the HF population"
Thanks for your thoughtful Editorial, @NealDixit and Saul Schaefer!
@dgfn_ev @YoungDgk @MarcusSaemann @hswapnil
ahajournals.org/doi/10.1161/…
Neal Dixit, MD retweeted
Costs? Intolerance? Inertia? Other? Primary reason for gaps in #GDMTworks endlessly debated.
🤔What if we had US physicians audit their own patient charts & report *WHY* they didn’t prescribe #GDMT for #HFrEF in each case?
🚨 Results in @JACCJournals
jacc.org/doi/epdf/10.1016/j.…
Will DANCAVAS be the most important screening trial in the last 50 years?
Interested to hear opinions!
Read our commentary 👇🏾
sciencedirect.com/science/ar…
Neal Dixit, MD retweeted
Cost-Effectiveness of GDMT for HFmrEF & HFpEF
jacc.org/doi/10.1016/j.jchf.…
@JACCJournals #JACCHF @gcfmd @boback @mvaduganathan @NealDixit @katieptr
Neal Dixit, MD retweeted
In #JACCHF @JACCJournals: cost effectiveness of medical tx for #HFmrEF & #HFpEF
*At current cost, MRA high value, SGLT2i intermediate value, & ARNI low value
*If generic, all are high value
🛑Need equitable access to meds for all!🛑
jacc.org/doi/10.1016/j.jchf.…
@gcfmd @NealDixit
Neal Dixit, MD retweeted
Generic priced options are here or just around the corner
Cost-Effectiveness of Medical Therapy for Heart Failure With Mildly Reduced and Preserved Ejection Fraction | JACC: Heart Failure jacc.org/doi/10.1016/j.jchf.…
@NealDixit @JACCJournals
Neal Dixit, MD retweeted
Should you wake up the patient when you preround?
Not only is there a #kittlesonrules for that, there's also a piece in this week's NEJM. Check it out :)
nejm.org/doi/full/10.1056/NE…
Neal Dixit, MD retweeted
Once again, nice work @NealDixit . I often start SGLT2- and MRA first as easy to get to targeted dose fast. Now its cost effective too!
What is a cost-effective GDMT strategy for HFmrEF/HFpEF?
We built a model w/ clinical trial data (TOPCAT, PARAGON-HF, EMPEROR/DELIVER) and simulated outcomes w/ regimens of MRA/SGLT2i/ARNi.
Best 💊 combo?
MRA + SGLT2i
ARNi ⬇️ value at current 💵
Treat HF with urgency!
Many thanks to the team of @gcfmd @katieptr @boback @mvaduganathan
Read the full article here:
jacc.org/doi/10.1016/j.jchf.…
Neal Dixit, MD retweeted
💶💵 Cost-Effectiveness of Medical Therapy for HFmrEF/HFpEF
💊MRA
💊💊MRA + SGLT2i
💊💊💊 MRA + SGLT2i+ARNI
↗️ in life years of HFmrEF/HFpEF👥
💊1.04/0.99
2️⃣💊1.58/1.54
3️⃣💊1.80/1.77
💊MRA therapy ICERs of $10,000 per r
QALY in both subgroups
💊💊ICER $113,000 per QALY in the
HFmrEF subgroup and $141,000 in the HFpEF subgroup.
💊💊💊ICERs>$250,000 per QALY in both subgroups.
💡👥 with HFmrEF/HFpEF ↗️ use of MRA and SGLT2i therapies should be encouraged
Via @JACCJournals @mvaduganathan @gcfmd @NealDixit &cia
📁 jacc.org/doi/10.1016/j.jchf.… – at Denia, Spain
Neal Dixit, MD retweeted
Cost effectiveness analysis of 💊 Rx in HFmrEF/HFpEF
Timing of generic pricing is 🔑
Cost-Effectiveness of Medical Therapy for Heart Failure With Mildly Re... sciencedirect.com/science/ar…
@boback @NealDixit @JACCJournals








































